Tag » Bms

Exelixis to partner with BMS in immunotherapy cancer trials

San Francisco-based biotech Exelixis is to team with Bristol-Myers Squibb in a series of trials investigating its own drug combined with BMS’ Opdivo. 

Initially, the collaboration will test Exelixis’ Cabometyx (cabozantinib) – a small molecule inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) – in combination with either one of or both Opdivo and Yervoy – BMS’ two leading PD-1 inhibitors – in a phase 3 trial in kidney cancer. 142 kata lagi

Pharma

BMSCE mechanical admission-2017 Bangalore

mechanical engineering-B.M.S. College

B.M.S. College of Engineering admission

B.M.S. College of Engineering (BMSCE) Businayana Mukundadas Sreenivasaiah College of Engineering is an autonomous engineering college in Basavangudi, Bangalore, India. 557 kata lagi

Admission

Hide No Longer - Burning Mouth Syndrome

Yesterday, an old friend reached out to me through Facebook and said she had a friend who was having a “burning tongue,” and she remembered that I had said something about that at some point. 237 kata lagi

Burning Mouth Syndrome

chemical engineering-BMS college admission 2017

 chemical engineering B.M.S. College of Engineering admission

B.M.S. College of Engineering

B.M.S. College of Engineering (BMSCE) Businayana Mukundadas Sreenivasaiah College of Engineering is an autonomous engineering college in Basavangudi, Bangalore, India. 556 kata lagi

Admission

MSD's Keytruda granted FDA priority review as first and second-line bladder cancer therapy

MSD’s two filings for Keytruda’s use in bladder cancer treatment have been accepted by the US FDA and given priority review status. 

The first filing is for Keytruda’s use as a first-line treatment in patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin treatment. 411 kata lagi

Pharma

BMS' Opdivo given US approval for treatment of bladder cancer

Bristol-Myers Squibb’s lead PD-1 inhibitor Opdivo has received approval from the US Food and Drug Administration for the treatment of bladder cancer. 

Opdivo (nivolumab) – a drug that reveals cancer cells to the immune system – can now be used in the US to treat previously treated locally advanced or metastatic urothelial carcinoma, the most common form of bladder cancer. 226 kata lagi

Pharma

Merck to pay BMS, Ono $625m plus royalties in patent settlement

Merck & Co are to pay Bristol-Myers Squibb and Ono $625 million plus 6.5% in royalties on Keytruda sales, settling its ongoing patent fight with both parties.  164 kata lagi

Pharma